Equity award vests for agilon health (NYSE: AGL) Chief Legal Officer

Rhea-AI Filing Summary

agilon health, inc. Chief Legal Officer Denise Zamore reported equity compensation activity tied to performance-based restricted stock units (PSUs). An award granted on April 14, 2023 fully vested on March 9, 2026 after agilon health achieved 42% of predetermined Revenue and Adjusted EBITDA goals over the three-year period from January 1, 2023 through December 31, 2025.

Each vested PSU settled into one share of common stock, resulting in 5,535 shares reported as acquired. In connection with this net settlement, 2,056 shares of common stock were withheld by the company at $0.5999 per share to satisfy income tax withholding and remittance obligations, which the disclosure notes does not represent a sale. Following these transactions, Zamore directly holds 446,604 shares of common stock, a figure that includes restricted stock units.

Insider Trade Summary

2 transactions reported

Net Buy 2 txns

Insider Zamore Denise

Role Chief Legal Officer

Bought 5,535 shs ($0.00)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,535	$0.00	--
Tax Withholding	Common Stock	2,056	$0.5999	$1K

Holdings After Transaction: Common Stock — 448,660 shares (Direct)

Footnotes (1)

1. This award was granted on April 14, 2023 and all remaining performance-based restricted stock units (PSUs) subject to the award vested on March 9, 2026. The number of PSUs that vested was determined based on agilon health's predetermined Revenue and Adjusted EBITDA goals over a three-year period from January 1, 2023 through December 31, 2025. Total attainment achieved was 42%. Each PSU represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of PSUs in shares of common stock on their scheduled vesting date. Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent a sale. Includes restricted stock units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zamore Denise

(Last) (First) (Middle)

C/O AGILON HEALTH, INC.

440 POLARIS PARKWAY, SUITE 550

(Street)

WESTERVILLE OH 43082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
agilon health, inc. [ AGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		P		5,535(1)(2)	A	(3)	448,660	D
Common Stock	03/09/2026		F		2,056(4)	D	$0.5999	446,604(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This award was granted on April 14, 2023 and all remaining performance-based restricted stock units (PSUs) subject to the award vested on March 9, 2026.

2. The number of PSUs that vested was determined based on agilon health's predetermined Revenue and Adjusted EBITDA goals over a three-year period from January 1, 2023 through December 31, 2025. Total attainment achieved was 42%.

3. Each PSU represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of PSUs in shares of common stock on their scheduled vesting date.

4. Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent a sale.

5. Includes restricted stock units.

Remarks:

	/s/ Mimi Yang, as Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did agilon health (AGL) Chief Legal Officer Denise Zamore report?

Denise Zamore reported vesting of performance-based restricted stock units that settled into 5,535 shares of agilon health common stock. This reflects equity compensation tied to multi-year performance goals, not an open-market trading transaction.

How were the agilon health (AGL) PSUs for Denise Zamore structured and measured?

The PSUs were granted April 14, 2023 and measured agilon health’s Revenue and Adjusted EBITDA performance from January 1, 2023 through December 31, 2025. The company achieved 42% of the predetermined goals, which determined how many units vested into common shares.

Did the agilon health (AGL) Form 4 show any open-market sale by Denise Zamore?

The Form 4 shows shares withheld to cover taxes, not an open-market sale. Specifically, 2,056 shares were retained by agilon health at $0.5999 per share to satisfy income tax withholding from the PSU settlement, which the filing states does not represent a sale.

What is Denise Zamore’s agilon health (AGL) shareholding after the reported PSU vesting?

After the PSU vesting and related tax withholding, Denise Zamore directly holds 446,604 shares of agilon health common stock. The disclosure notes this total includes restricted stock units in addition to already held common shares.

Over what period were agilon health (AGL) performance goals measured for Denise Zamore’s PSUs?

The performance period for the PSUs ran from January 1, 2023 through December 31, 2025, a three-year span. agilon health’s achieved Revenue and Adjusted EBITDA over this timeframe determined that 42% of the targeted performance was met for vesting.